Investor Presentation
Released
Released
Announcement PDF
COMMERCIALISING
CELLULAR
IMMUNOTHERAPIES
“EAST TO WEST”
ADALTA LIMITED (ASX:1AD)
|
INVESTOR PRESENTATION
| MAY 2025
AdAlta Limited (ASX:1AD) | Investor Presentation |
May 2025 |
1
IMPORTANT NOTICE & DISCLAIMER
Investment in AdAlta is subject to investment risk, including possible loss of income and capital invested. AdAlta does not guarantee any particular
rate of return or performance, nor do they guarantee the repayment of capital.
This presentation is not an offer or invitation for subscription or purchase of or a recommendation of securities. It does not take into account the
investment objectives, financial situation and particular needs of the investor. Before making any investment in AdAlta, the investor or prospective
investor should consider whether such an investment is appropriate to their particular investment needs, objectives and financial circumstances and
consult an investment advisor if necessary.
This presentation may contain forward-looking statements regarding the potential of the Company’s projects and interests and the development and
therapeutic potential of the company’s research and development. Any statement describing a goal, expectation, intention or belief of the company is
a forward-looking statement and should be considered an at-risk statement. Such statements are subject to certain risks and uncertainties,
particularly those inherent in the process of discovering, developing and commercialising drugs that are safe and effective for use as human
therapeutics and the financing of such activities.
There is no guarantee that the Company’s research and development projects and interests (where applicable) will receive regulatory approvals or
prove to be commercially successful in the future. Actual results of further research could differ from those projected or detailed in this presentation.
As a result, you are cautioned not to rely on forward-looking statements. Consideration should be given to these and other risks concerning research
and development programs referred to in this presentation.
AdAlta Limited (ASX:1AD) | Investor Presentation |
May 2025 |
2
ADALTA: NEXT GENERATION CELL & PROTEIN THERAPEUTICS
“East to West” cellular immunotherapy strategy
In-license next generation clinical stage assets from Asia, establish
Western manufacturing and generate clinical data for on-licensing
AdAlta is a clinical
stage biotech with its
clinical pipeline growth
powered by its “East to
West” cellular
immunotherapy
strategy building on
other valuable assets
Leverages our unique skills, regional ecosystem and business model to
create a leader in cellular immunotherapy for solid cancer patients
Bridges the gap between Asian innovation and Western biopharma
companies (and patients who can benefit from them)
Creates a series of capital efficient, short investment horizon assets
with frequent clinical milestones
Other valuable pipeline assets
Builds pipeline above first in class anti-fibrotic protein, AD-214, with
strategic partners sought for continued development into Phase II outside
the company, and world first pan-strain inhibitor of malaria parasites,
WD-34, with strategic partners sought to advance to proof of concept
AdAlta Limited (ASX:1AD) | Investor Presentation |
May 2025 |
3
ADALTA’S RENOUNCEABLE RIGHTS OFFER
Renounceable offer of two (2) New Shares for every three (3) Shares held by
Eligible Shareholders at the Record Date
•
Issue price 0.3 cents ($0.003) per New Share
•
51% discount to 15 day VWAP
One (1) New Option for every two (2) New Shares
•
Exercise price 1.0 cent ($0.01)
•
Three year term (expiry 3 June 2028)
To raise $1.29 million if fully subscribed to be used:
•
Advance a first CAR-T product in-licensing transaction for AdCella subsidiary
•
Advance business development transactions for AD-214 and WD-34
•
Evaluate other strategic options for the Company and, to the extent any
funds remain, fund general working capital
New Shares and New Options will be issued by AdAlta Ltd ACN 120 332 925 under and in accordance with a prospectus
prepared in accordance with s713 of the Corporations Act that was lodged with ASIC and ASX on 5 May 2025 (Prospectus).
The offer of the New Shares and New Options (Offer) will be made directly to Eligible Shareholders and will be accompanied
by a copy of the Prospectus. A person should consider the Prospectus in deciding whether to acquire the securities and to
acquire New Shares and New Options under the Offer. A person who decides to acquire the New Shares and New Options
under the Offer will need to complete the application form that will accompany the Prospectus. A copy of the Prospectus and
the Target Market Determination and further information regarding the offer can be obtained at:
https://investorhub.adalta.com.au/announcements. The Offer is being managed by Mahe Capital Pty Ltd ACN 634 087 684.
INDICATIVE TIMETABLE
DATE
Lodge transaction specific prospectus with ASIC and give to ASX
Lodge appendix 3B applying for quotation of New Shares and New
Options
Monday 5 May 2025
Shares commence quotation on an ‘ex’ basis (‘ex’ date)
Rights are quoted on a ‘deferred settlement basis’ from market open
Wednesday 7 May 2025
Record Date to participate in rights offer
Thursday 8 May 2025 at
7:00pm (Melbourne time)
Dispatch offer documents to eligible shareholders
Deferred settlement trading in rights ends
Tuesday 13 May 2025
Rights offer opens
Tuesday 13 May 2025
Rights trading ends at close of trading
Wednesday 21 May 2025
Securities commence quotation on a deferred settlement basis from
market open
Thursday 22 May 2025
Rights offer closes
Wednesday 28 May 2025 at
5:00 pm (Melbourne time)
1AD announces to market results of rights offer and notifies
underwriter of shortfall
Thursday 29 May 2025
Issue New Shares and New Options taken up under the pro rata
entitlement (together with any shortfall shares and underwritten
shares). Lodge appendix 2A applying for quotation of the New Shares
and New Options
Wednesday 4 June 2025
Deferred settlement trading ends
Wednesday 4 June 2025 on
market close
Normal trading of New Shares and New Options starts
Thursday 5 June 2025 on
market open
AdAlta Limited (ASX:1AD) | Investor Presentation |
May 2025 |
4
“EAST TO WEST” STRATEGY
CENTRAL TO ADALTA’S
GROWTH
AdAlta Limited (ASX:1AD) | Investor Presentation |
May 2025 |
55
“EAST TO WEST” STRATEGY OVERVIEW
AdAlta has clear aspirational
growth targets for its
“East to West” strategy
By end 2025
From 2026
Substantial value inflection potential by bringing “Eastern” cellular
immunotherapy innovations to “Western” regulated markets
Combining Asia's innovative T cell therapies for solid cancers and
Australia's manufacturing advantages leverages unique regional benefits
Exclusive focus on T cell therapies for solid cancers targets less
competitive markets while utilising proven cellular immunotherapies
Robust asset selection process yielding access to first/best in class,
highly differentiated products with clinical evidence of safety and efficacy
Three assets
secured*
One asset into
clinical trials
each year
Capital light model offers quick ROI potential: a single clinical trial to
value inflection using external capital and AdAlta product management
Highly scalable to become industry leader through systematic product
licensing and pipeline expansion opportunities
AdAlta Limited (ASX:1AD) | Investor Presentation |
* On track – three assets under exclusive negotiation
May 2025 |
6
RATIONALE FOR OUR STRATEGY
Market Opportunity
90%
34%
$20.3B
50%
2
61%
Cancers that are solid
tumours and remain
underserved by cellular
immunotherapies
CAGR of cellular
immunotherapy market and
market size by 20281
Revenue estimated to be
generated from solid
tumours by 2030;2 recent
FDA approvals setting stage3
Asia leads in total clinical
trials,4 providing a unique
innovation pool in which
AdAlta can lead
Competitive Advantage
•
Networks: Asia's rich innovation,
Australia's clinical and manufacturing
ecosystem, AdAlta's pre-IND to clinical
skills
•
Strategic sourcing: Disciplined asset
selection of highly differentiated assets
with clinical data in solid cancers
•
Unique value proposition: asset
financing for partners enables more
valuable exit; “East to West” reduces risk
for buyers
•
•
Capital-light: modest investment
leveraged with outside investment to
achieve a single inflection before exit
Scalable: replicable across multiple
assets
First Assets
Initial three assets under term sheet from
pipeline of 10 high-potential therapies
Armored CAR-T for lung,
gynaecological, pleural and
peritoneal cancers
First-in-class CAR-T for
advanced colorectal and
gastric
First-in-class CAR-T for
gastric and other epithelial
cancers
AdAlta Limited (ASX:1AD) | Investor Presentation |
May 2025 |
7
1. Grandview Research, “T-cell Therapy Market Size, Share & Trends Analysis” Feb 2021; 2. Polaris Market Research, “CAR-T Cell Therapy Market Share, Size, Trends, Industry Analysis Report”, June 2021 2. Alliance for Regenerative Medicine, Developer Data
Report Q3 2023; 3. https://www.fda.gov/vaccines-blood-biologics/approved-blood-products/amtagvi; https://www.fda.gov/vaccines-blood-biologics/aucatzyl 4. GlobalData, Pharma Intelligence Centre, Clinical Trials Database (accessed 5 April 2024)
BECOMING A VALUATION MULTIPLIER FOR ASIAN PARTNERS
3
3
On-licensing:
Establish global
manufacturing network
and on-license to
commercialisation
partners. AdAlta and
partner share increased
value that partner could
not achieve on their own
In-license market leading
assets from Asia (“East”):
Low acquisition cost. By
financing to next inflection
point AdAlta acquires a
share of the asset at exit
1
2
Build value by transferring to “West” under AdAlta management:
Apply Western regulated manufacturing, obtain first Western regulated
clinical data in Australia to create substantial inflection point for big pharma;
managed by AdAlta and leveraged with third party investment
AdAlta Limited (ASX:1AD) | Investor Presentation |
May 2025 |
8
VALUE AT EXIT: PHASE I CAR-T LICENSING TRANSACTIONS
Deal stage
Lead indications
Total
value (US$m)
Upfront
(US$m)
MAGE-A4 targeting TCR T
cell therapy
Phase 2
(ongoing; global)
Head & neck cancer
665
85
Nov-23
DLL3 targeting autologous
CAR-T cell therapy
Phase 1
(ongoing; US)
SCLC, LCNEC
1,110
100
May-23
CD20 and CD19/20directed autologous CAR-T
cell therapy
Phase 1
(completed; China)
B-cell NHL,
Follicular lymphoma, mantle
cell Lymphoma, DLBCL
n/a
245
Jan-23
CART-ddBCMA
Phase 2
(ongoing; US)
Multiple myeloma
n/a
325
Dec-22
Anti-BCMA CAR-T cell
therapy
P1b
(ongoing; Israel)
Multiple myeloma
34.55
1.5
Dec-20
Mesothelintargeted autologous
and allogeneic CAR-T
cell therapy
Phase 1
(ongoing for autologous therapy;
US)
Peritoneal /
pleural mesothelioma
670
60
MEDIAN
667.5
92.5
Date
Drug(s)
May-24
Licensor
Licensee
Global top 25 oncology pharma companies investing in
autologous cell therapy (licensing, M&A, CVC)
5y
72%
2y
44%
AdAlta Limited (ASX:1AD) | Investor Presentation |
Source: Company press releases, GlobalData; Beacon Intelligence
May 2025 |
9
PROGRESS AND POTENTIAL
Asset acquisition stream
• Technical and on-site diligence essentially complete
• Minor adjustments to timelines, sequencing and financial
milestones being finalized – on track for first asset license Q2 2025
We are here
today
Financing stream
• Seed financing from SYNBV, subject to closing conditions
• On going discussions with global financial partners – generally
conditional on securing first license
“East to West” cell
therapy strategy
announced;
MoU with SYNBV
10 assets in
diligence
Consultant CMO
appointed
Three in-licensing
term sheets
signed (90-120
days exclusive
negotiation)
Apr-2024
Carina Biotech
collaboration to
develop i-body®
bi-specific CAR-T cells
May-2024
Preferred
manufacturing
partnership with
CTPL
Jul-2024
Oct-2024
1st non-binding
in-licensing
term sheet
Three high value
assets secured (F)
2028+
2026+
End-2025
2H-2025
1H-2025
Aug-2021
First technology
transfer to
commence (F)
First IND
approval (F)
Australian clinical
trial data facilitates
pivotal studies,
licensing agreements
and asset sales
Oct-2024
Initiate one new
clinical trial per year
(target)
More term sheets in
development
AdAlta Limited (ASX:1AD) | Investor Presentation |
May 2025 |
10
THREE ASSETS UNDER EXCLUSIVE DUE DILIGENCE
Armored-CAR-T term sheet #1
CAR-T term sheet #2
CAR-T term sheet #3
Lung, mesothelioma, ovarian, cervical,
pancreatic, colorectal
Epithelial solid cancers incl. colorectal,
lung and gastric
Gastric, gynaecological and other
epithelial cancers
Patients worldwide p.a
>1.5 million
>1.5 million
>1.65 million
First and best in class
Yes
Yes
Yes
High potency, armoured to overcome
immune suppression
Rapid, virus free manufacturing
Selective activation and safety kill switch
Potential for multi-dosing without
lymphodepletion, IP administration
First to achieve US FDA IND on this target
Short manufacturing process
Targets tumour, circulating tumour cells
and cancer stem cells
3 (n=33)
2 (n=9, includes 4 with 2+ doses)
2 (n=18)
Safety and efficacy
Efficacy substantially superior to current
second line standard of care; manageable
safety
Activity/efficacy signals in heavily pretreated patients; preliminary
understanding of safety
Response above third line and comparable
to second line therapies with high disease
control rate in advanced gastric cancer
Regulatory engagement
China Phase I IND approval
US Orphan Drug Designation and pre-IND
meeting
Extensive and compelling preclinical
package in multiple difficult tumour
models
China and US gastric cancer and China
pan-cancer Phase I INDs approved
US Orphan Drug Designation (gastric)
Competition
No competitive product beyond Phase II
trials
Very few competitor products against this
target
Other targets in development for these
indications do not have same tumor
coverage
IP protection
US, EU, China and others
Target binding and armouring sequences,
transduction technology
US, EU, China and others
Target binding sequence, method of
avoiding lymphodepletion, method of
optimising CAR
US, EU, China and others
Target binding sequence; CAR-T product
and use of CAR-T against circulating
tumour cells
Field
Key advantage
Investigator Initiated Trials in
China
AdAlta Limited (ASX:1AD) | Investor Presentation |
May 2025 |
11
1. FIRST IN CLASS ARMOURED CAR-T
Target market
• Mesothelioma, lung cancer plus ovarian, cervical, pancreatic, colorectal
Advanced, solid cancer patient:
sustained response to armored-CAR-T
• More than 1.5 million relapsed, refractory or metastatic patients requiring second-line treatment (2L) worldwide
Product differentiation
Clinical data
• First in class, best in class
• Advanced mesothelioma: ORR 63.5%; CR 9%; PR
54.5%; SD 36.4 %; mPFS 5 months; mOS > 40
months
• PD1 armored CAR-T
• Non-viral vector transduction – lower cost
• Rapid (30h) manufacturing process – lower cost,
increased capacity
• High potency (low dose required)
• Substantially superior to second line (2L) standard
of care (SoC) on all measures
• Activity in other cancers, confirmed response in OC
• Manageable safety profile
Competitive position
Development status
• Excellent target which has previously struggled to
advance beyond Phase II
• Three Investigator Initiated Trials (IIT) in China (33
advanced cancer patients treated)
• Armoring provides potential to overcome lack of
potency of other CAR-Ts and modalities; enables
endogenous as well as CAR-T cells
• Approved for Phase I trials as investigational new
drug (IND) by China NMPA
• Big pharma focused on bispecifics, antibody drug
conjugates (ADCs): all at Phase I
• No directly competitive product >Phase II
• Orphan drug designation (ODD) in US for one
indication
• Patent applications protecting CAR and armoring
binders and transduction technology
AdAlta Limited (ASX:1AD) | Investor Presentation |
May 2025 |
12
2. FIRST IN CLASS CAR-T
Target market
• Colorectal cancer and a wide range of epithelial solid cancers including gastric and lung
• More than 1.5 million relapsed or refractory patients worldwide each year
• 130,000 3L colorectal cancer patients each year
Product differentiation
Clinical data
• First in class – novel target
• Activity in 9 heavily pre-treated patients
• Potential for multi-dosing with low/no
lymphodepletion
• 4/9 received two or more doses
• Potential for IP and IV administration
• Selective activation at high antigen density
• One case of complete resolution, two of reduced
severity of malignant ascites
• Activity at very low doses, kill switch incorporated
• Kill switch tested
• Demonstrated manufacturing on lower cost
Cocoon platform
• Early data suggests manageable toxicity profile
Competitive position
Development status
• Limited competitor products against this target
family; no CAR-T products against this target
• Compelling preclinical package in multiple difficult
tumor, rechallenge models
• This target most widely expressed of family in
cancer
• Two Investigator Initiated Trials (IITs) in China (nine
very advanced patients treated)
• Experienced, networked development team
• Two major CAR-T cancer centres engaged
• Western clinical centres already engaged
• Patent applications protecting CAR binder, avoiding
lymphodepletion, method of optimising CAR
Complete resolution of
malignant ascites in Stage IV GI
cancer patient
5,000
5,000
• Engraftment in 8/9, 5/5 without lymphodepletion
3,000
1,000
50
Day -3
Day 1 Day 9
(CAR-T)
0
Day 11 Day 18 Day 22
AdAlta Limited (ASX:1AD) | Investor Presentation |
May 2025 |
13
3. FIRST IN CLASS CAR-T
Target market
• Gastric cancer and other epithelial cancers including gynaecological cancers
• More than 1.5 million relapsed or refractory patients worldwide each year
Comparative efficacy versus
standard of care
• 150,000 advanced gastric cancer patients each year
Product differentiation
Clinical data
• First in class
• Up to 40% ORR and >40 weeks mOS, well in excess
of current 3L therapy and comparable with 2L in
advanced gastric cancer at current RP2D
• First CAR-T on this target to achieve US FDA IND
• Targets circulating tumour cells and cancer stem
cells as well as primary tumour cells
>40
40
38-46
27-45
• 90% disease control rate
• Short (5d) manufacturing process with potential to
reduce COGS 50%
• Demonstrated safety
Competitive position
Development status
• Target well known but only recently attracting
renewed interest as therapeutic target
• 18 patients treated in two Investigator Initiated Trial
in China (10 assessed for efficacy)
• Expression only partially overlaps with other
epithelial cancer targets – protected patient pools
• China IND for advanced gastric cancer; 2nd IND for
other cancers pending
• Team launched one of first CAR-T products in
China as Fosun-Kite
• US FDA IND for advanced gastric cancer
• Patent applications protecting CAR binder, CAR-T
product and use against circulating tumour cells
24
10
ORR (%)
Product X
mOS (w)
2nd line
Third line
AdAlta Limited (ASX:1AD) | Investor Presentation |
May 2025 |
14
AD-214: A NEW APPROACH
TO FIBROSIS
AVAILABLE FOR PARTNERING
AdAlta Limited (ASX:1AD) | Investor Presentation |
May 2025 |
15
15
MONETISING FIBROSIS DISEASE DRUG CANDIDATE AD-214
Investment to date has built strong value proposition
First in class molecule
targeting established mode
of action in fibrotic disease
Pre-clinical efficacy in
multiple animal models of
fibrotic disease – derisks
clinical studies in US$b
indications
Phase I successfully
completed (two studies)
Clinically viable dosing
regimen
Strong intellectual property,
regulatory position
✓
Competitively positioned as only antibody-like
therapeutic entering late-stage development pipeline
Key Priority: Seek out-licensing or third-party investment to
unlock next level of value
Advisors engaged; pipeline of active discussions
Product development priorities
✓
Led by Idiopathic Pulmonary Fibrosis (IPF): TAM
US$4.3b
1. Generate clinical proof of concept (efficacy)
✓
Multiple US$b indication potential: kidney, eye, cancer
• Demonstrate efficacy signals in patients
• IV or SC administration
✓
Well tolerated, evidence of target binding
✓
Intravenous (IV) every 2 weeks established
✓
Subcutaneous (SC) every week feasible
✓
Models linking PK/PD and preclinical efficacy to
establish dose
✓
Patents protecting asset to 2036 and beyond
✓
US FDA Orphan Drug Designation for IPF
✓
10-12 years market exclusivity (US, EU)
• Substantially increases number of potential licensing partners
Design and execute clinical strategy in IPF patients
2. Develop market preferred formulation
• Weekly SC preferred over two weekly IV
• Enhanced market share, reduced COGS
• Achieves commercial ready COGS
Develop formulation, integrate into clinical trials
AdAlta Limited (ASX:1AD) | Investor Presentation |
May 2025 |
16
UNDERSERVED AND LARGE FIBROTIC DISEASE MARKET
Many other fibrosis market opportunities2
IPF market is underserved today
•
Poor efficacy: Existing therapies slow but do not halt
progression and do not significantly extend life expectancy
•
Side effects: Their side effects result in 30-50% of patients
discontinuing therapy after one year
•
Expensive: US$136,000 pa cost of treatment in US
Global IPF sales (US$ billion)¹
8-year CAGR: 4.7%
Lung
US$4b
5.11
Kidney
US$10b
Eye
US$15b
Per Cancer
US$1b
4.30
3.55
New drivers of incidence may include:
2019
2022
•
Re-emergence of silicosis
•
Long COVID3
2027E
AdAlta Limited (ASX:1AD) | Investor Presentation |
1. GlobalData, Idiopathic Pulmonary Fibrosis: Competitive Landscape, April 2023; Roche and Boehringer Ingelheim financial reports,AdAlta analysis 2. GlobaData,
disease analysis reports 3. PM George, et al, “Pulmonary fibrosis and COVID-19: the potential role for antifibrotic therapy”, Lancet published online May 15, 202
May 2025 |
17
PHARMA COMPANIES VALUE IPF/FIBROSIS ASSETS
Transaction
Upfront payment to
licensor
Contingent
milestones
Clinical Phase at
transaction
Aug-22
License
US$100m
US$600m
2 complete
Apr-20
Acquisition
US$45m
Not disclosed
2a complete
Nov-19
Acquisition
US$390m
US$1,000m
2 complete
Jan 23
China only license
US$76m
US$240m
2 underway
Feb 23
Acquisition
US$425m
N/A
2a underway
Jan 25
License
US$99m
US$687m
2 (Ready)
Nov-21
Acquisition
US$353m
N/A
2 (Ready)
Nov-20
License
€25m
€295m
2 (Ready)
Sep-21
License
US$152m
US$450m
2 (Ready)
Feb-21
License
Not disclosed
US$517.5m
1 underway
Jul-19
License
€45m
€1,100m
1 underway
Oct-22
Acquisition
US$255m
Not disclosed
Pre-clinical
(+ platform)
Date
Licensor/target
Licensee/acquirer
AD-214 is
Phase 2 (ready)
AdAlta Limited (ASX:1AD) | Investor Presentation |
Source: Company press releases, GlobalData; Beacon Intelligence
May 2025 |
18
WD-34 I-BODY: A POTENTIAL
BREAKTHROUGH IN MALARIA
AVAILABLE FOR PARTNERING
AdAlta Limited (ASX:1AD) | Investor Presentation |
May 2025 |
19
19
WORLD FIRST PAN-SPECIES HIGH POTENCY ANTI-MALARIAL
WD-34 i-body has potential to transform malaria treatment
Malaria remains a
global killer
Meaningful global
market
Limitations of
current therapies
WD-34 i-body
offers a potential
breakthrough
Opportunity
✓
247 million cases, 619,000 deaths in 20211
✓
Re-emerging in US and EU2
✓
New markets in related tick-borne diseases eg Babeziosis
✓
US$250-500 million for travellers and deployed personnel
✓
Market limited by poor efficacy, cost of current therapies in emerging
markets
✓
Small molecules: rapid development of resistance and inconvenient dosing
regimens
✓
Antibodies: typically strain specific or limited inhibition
✓
Vaccines: limited efficacy; antigen variability
✓
Novel discovery strategy targeted a conserved region of AMA-1 protein
✓
Recognises AMA1 from multiple malaria (Plasmodium) species as well as
Babesia and Toxoplasma
✓
High potency inhibition of multiple life cycle stages
✓
IP filed
✓
Long acting, single dose (3-6mo) prophylaxis for deployed personnel,
travellers
✓
Seasonal prophylaxis for children in endemic malaria regions
✓
Novel method of antigen identification for more effective vaccines
Strategy: seeking non-dilutive and commercial
partners to advance outside AdAlta
Active discussions to spin out asset
AMA1
PPM
WD-34
i-body
Host red blood cell
Model of plasmodium falciparum malaria (PPM) with
AMA1 / RON2 protein complex and host erythrocyte 3
showing how WD-34 inhibits invasion via AMA1
AdAlta Limited (ASX:1AD) | Investor Presentation |
1. World Health Organisation, World Malaria Report 2022, https://www.who.int/publications/i/item/9789240064898 2. https://publichealth.jhu.edu/2023/malarias-comeback-in-the-us and
https://blogs.biomedcentral.com/bugbitten/2023/08/25/locally-acquired-malaria-in-europe-and-the-us/ 3. Adapted from Drew et al. Cell. Mol. Life Sci. 80, 74 (2023) using BioRender
May 2025 |
20
CORPORATE
INFORMATION
AdAlta Limited (ASX:1AD) | Investor Presentation |
May 2025 |
21
21
CORPORATE SNAPSHOT
AdAlta Limited
Code
ASX:1AD
Market Capitalisation
$4.0m
Enterprise Value
$3.2m
Cash (31 March 2025)
$0.8m
Significant Shareholders
Sacavic Group
15.8%
Meurs Group
14.5%
Platinum International
Healthcare Fund
12.7%
~1,500 other shareholders
57%
Specialist in next-generation cell and protein
therapeutics for fatal diseases
First three term sheets signed of "East-toWest" cell therapy strategy, with team and
network in place
Capital-light, highly scalable model with
numerous value inflection points in the rapidly
growing cellular immunotherapy market
AD-214, a new approach for fibrotic diseases,
(Phase 1 trials complete) and AMA1 i-body
first in class anti-malarial now available for
partnering
AdAlta Limited (ASX:1AD) | Investor Presentation |
May 2025 |
22
EXPERIENCED TEAM WITH GLOBAL REACH
Board
Paul MacLeman, DVM
Chair
Executive
Angus Tester, PhD
Senior Manager,
Projects and Programs
Tim Oldham, PhD
CEO / Managing Director
Janette Dixon, DBA
“East-to-West” Strategy
AD-214: Fibrosis
Kevin Lynch
TBA - engaged
Prof Andrew Wilks
Joseph Tyler
Consultant CMO
Consultant CMO
VC Advisor
Consultant CMC Expert
Head of Business
Development
Michelle Burke
DHC secondment
Independent Director
Prof Tamera Corte
Head of Asset
Development
Clinical Advisory Board
Andrew O’Brien, PhD
Dr David Fuller
Head of Corporate
Development
Steve Felstead
Independent Director
Iain Ross
Independent Director
Darryn Bampton
Director, Clinical and
Regulatory Operations
AdAlta has been
building capability for
its “East-to-West”
strategy
Clinical Advisory Board
Prof Toby Maher
Clinical Advisory Board
AdAlta Limited (ASX:1AD) | Investor Presentation |
May 2025 |
23
TRANSACTION-BASED GROWTH STRATEGY IS BEING DELIVERED
“East to West” cellular
immunotherapy growth strategy
leveraging regional and business
model advantages in high value, high
growth sector is now delivering
The first three assets under
exclusive due diligence for the “East
to West” clinical pipeline to create a
leader in cellular immunotherapy for
solid cancer patients
Experienced team and accessible
global network ready to execute a
diverse pipeline of opportunities
AD-214, available for partnering to
unlock value created, heading to
Phase II (US$4.3b IPF market),
substantially de-risked by Phase I
study clinical readouts
WD-34, available for partnering to
create additional value
Attractive valuation relative to
commercial potential of pipeline –
potential for a single transaction to
materially influence valuation
AdAlta Limited (ASX:1AD) | Investor Presentation |
May 2025 |
24
FOR MORE INFORMATION PLEASE CONTACT:
TIM OLDHAM
CEO & MANAGING DIRECTOR
+61 403 446 665
T.OLDHAM@ADALTA.COM.AU
IR@ADALTA.COM.AU
WWW.ADALTA.COM.AU
AdAlta Limited (ASX:1AD) | Investor Presentation |
May 2025 |
25
THE MARKET OPPORTUNITY
T cell solid cancer therapy: the next frontier for cellular immunotherapy
What is T-cell therapy?
Involves re-engineering and
turbo-charging patient’s
own immune cells to “see”
cancer
Living drug, single dose,
potentially curative
6 FDA-approved CAR-T
therapies since 2017
transformed blood cancer
outcomes, but so far only
for blood cancers
>US$2.6B earned
in 20221
Complete response rates:2
83% r/r pALL
51-65% r/r LBCL
78% r/r MM
In 2024, FDA approved two
T cell therapies for solid
cancer (melanoma,
sarcoma), opening the
much larger solid cancer
market segment3
50% of US$20.3B forecast
cellular immunotherapy
revenue for 20284
1. Company websites and financial filings
2. Kymriah, Yescarta and Carvytki prescribing information; r/r = relapsed/refractory; pALL – paediatric
acute lymphoblastic leukemia, LBCL = large B cell lymphoma, MM = multiple myeloma
3. https://www.fda.gov/vaccines-blood-biologics/approved-blood-products/amtagvi;
https://www.fda.gov/vaccines-blood-biologics/aucatzyl
4. Grandview Research, “T-cell Therapy Market Size, Share & Trends Analysis” Feb 2021; Polaris Market
Research, “CAR-T Cell Therapy Market Share, Size, Trends, Industry Analysis Report”, June 2021
AdAlta Limited (ASX:1AD) | Investor Presentation |
May 2025 |
26
ACCESSING QUALITY ASSETS FROM ASIA
Quality Asia cellular
immunotherapy pipeline,
barriers to reach West
“At JPM Week, biopharma
innovation from China and Asia
was the topic of conversation —
reshaping the global biopharma
landscape”4
Flow of innovation from Asia to the West is hampered by: lack of capital in Asia, lack of Western
experience and networks, opportunity cost for large biopharma to conduct due diligence, difficulty
transferring data and know-how, lack of patient diversity in clinical data and geopolitical challenges.1
Cellular immunotherapy developers 20
Share your feedback
Discover